VCBeat Health Contact Us
Home Johnson & Johnson Reports Q2 2025 Revenue of $23.7B, Cardiovascular Segment Surges 23.5% Driven by Electrophysiology and Abiomed

Johnson & Johnson Reports Q2 2025 Revenue of $23.7B, Cardiovascular Segment Surges 23.5% Driven by Electrophysiology and Abiomed

Jul 17, 2025 10:30 CST Updated 10:30
Johnson & Johnson

Medical Device R&D and Manufacturer

Johnson & Johnson Announces 2025 AnnualQ2 financial reports, its Q2 revenue reached237Billion USD (+5.8%), ProfitRecently55Billion USD (+18.2%). Johnson & Johnson's performance this quarter was still very good, with its salesSales exceeded market expectations (MarketPredicted revenue is229(Billion USD)。
Image
Among them, the medical device business of Johnson & Johnson reached a sales volume of 8 this quarter.$500 million（+7.3%），Electrophysiology products in the cardiovascular field, Abiomed products, and general surgical wound closure products are the main growth drivers.
Image
In Johnson & Johnson's medical device business, the cardiovascular sector remains the best-performing segment (with sales reaching $2.313 billion, representing a year-over-year increase).23.5%), while the orthopedic business performed the worst (Sales reached $2.305 billion, a year-on-year increase of 0.3%. Ophthalmology and surgical sales were $1.369 billion (+6.5%) and $2.555 billion (+2.7%), respectively.
Image
Cardiovascular BusinessTo provide a continuous driving force for the rapid growth of Johnson & Johnson's medical devices. Among themElectrophysiology products and cardiac interventional pumps are key to the growth of the cardiovascular business. BesidesAbiomed contributed to 18.2% of the growth, while sales in the more competitive electrophysiology business also increased by 11%. The electrophysiology business not only achieved$1.47 billion in sales, and the decline has been reversed (Q1 performance showed a nearly 2% year-on-year decline).
Electrophysiology business returns to high-speed growth, thanks toVaripulse PFA (which has completed over 10,000 surgeries globally).Currently, Johnson & Johnson isVaripulse has been approved for marketing in countries or regions, accelerating the commercialization process, and surgeries have already commenced in new markets such as China and Australia.
Johnson & Johnson Shows Determination in Electrophysiology, Tim Schmid, Chairman of Johnson & Johnson’s Global Medical Technology, States in ElectrophysiologyNever Back DownWill compete with Boston Scientific and Medtronic to the end, since Johnson & Johnson pioneered this great track.
"Given that we pioneered this field (electrophysiology), this business is of extraordinary significance to us. I know some analysts lost confidence in us earlier this year, but we remain highly confident in our ability to maintain our global market leadership in the long term. Sales in the electrophysiology division grew by more than 9% quarter-on-quarter from the first quarter, and the growth rate accelerated further in the second quarter. It is perhaps fair to say at this point that it could be the most exciting category in medical technology. Let me make one thing clear: we are not backing down."
---Tim Schmid  Chairman of Johnson & Johnson Global Medical Technology
Executive Evaluation
"Strong performance highlights Johnson & Johnson's unique diversified business advantages across medical technology and innovative pharmaceuticals. Our product portfolio and R&D pipeline lay the foundation for accelerated growth in the second half of the year, with anticipated approvals and launches of disruptive therapies in lung cancer, bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular fields, extending and improving human lives in a transformative way."
---Joaquin Duato Johnson & JohnsonChairman and Chief Executive Officer
Johnson & Johnson New Product Launch
Tariff
Johnson & Johnson forecasts full-year tariff costs to be approximately $200 million, all related to its medical technology business. This figure is half of what the company predicted during its Q1 earnings call.
Future
Johnson & Johnson Plans to Submit De Novo Application for Its Ottava Soft Tissue Surgical Robot to the FDA in the First Quarter of 2026. Johnson & Johnson Hopes the System Can Capture a Share of the Soft Tissue Robotics Market Dominated by Intuitive Surgical.